Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Vitrolife AB Announces Private Placement Fully Subscribed


Wednesday, 31 Oct 2012 12:00pm EDT 

Vitrolife AB (Vitrolife) announced that The Extraordinary General Meeting of Vitrolife held September 24, 2012 adopted a resolution regarding a private placement of EUR 1.352.315 in order to partly finance the acquisition of Cryo Management Ltd (Cryo). It was decided that the new shares were to be issued at a subscription price per share corresponding to the average closing price for Vitrolife's shares during the 15 trading days immediately subsequent to the Vitrolife’s shares being traded exclusive of entitlement to distribution of shares in Xvivo Perfusion AB, based on an average EUR/SEK exchange rate during the aforesaid 15 trading days. The Board of Directors has resolved to determine that the Company’s share capital shall be increased with not more than SEK 273.530,34 by an issue of not more than 268,167 shares and that the subscription price for each share shall be EUR 5.0428 based on an average closing price of 43,29 and an average EUR/SEK exchange rate of 8,5852. The new share issue was fully subscribed for. Payment for the new shares was made by way of set-off of claims that the subscribers had on Vitrolife. The new issued shares are estimated to be registered at Euroclear Sweden AB during November 2012. After the new share issue is finalized, the total number of shares in Vitrolife AB is estimated to 19.830.936. 

Company Quote

120.0
2.0 +1.69%
11 Jul 2014